Wuhan Union Hospital Licenses Intelligent Laparoscopic Uterine Manipulator Patent for RMB 200,000

Recently, Union Hospital, Tongji Medical College of Huazhong University of Science and Technology, released a public notice on the transformation of scientific and technological achievements, proposing to transfer the patent for "A Uterine Elevating Device for Gynecological Laparoscopic Surgery" to Hunan Kemaisen Medical Technology Co., Ltd., with a transfer fee ofRMB 200,000. The inventors of this patented technology are Zhang Lufang and her team.

Image from the official website of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

A transfer price of 200,000 yuan is not considered a large sum in the conversion of medical patents, but thisBehind the deal lies a heating-up sector—Intelligent Upgrade of Laparoscopic Uterine Manipulators.

1. Clinical pain points have long been neglected.In gynecological laparoscopic surgery, uterine manipulation is a critical step for exposing the surgical field and completing hysterectomy. However, uterine manipulators used in clinical practice have long had significant shortcomings:

Limited Swing—Most conventional devices are limited to anterior-posterior movement, making it difficult for surgeons to adjust uterine morphology from multiple angles as required during surgery; they often prove inadequate when dealing with deep anatomical structures.Poor adaptability—The uterine manipulator cup has a fixed diameter, necessitating frequent instrument changes for patients with significant variations in uterine size, thereby increasing the risk of surgical interruptions;Instability of Fixation—The uterine manipulator has a monolithic design, which prevents effective conformity to the inner uterine wall, leading to slippage and displacement during surgery and compromising operational precision and safety.

While these pain points may seem "tolerable," the market's demand for intelligent uterine manipulators is being unleashed as the volume of minimally invasive gynecological surgeries continues to grow and surgical complexity increases.

2. The window for intelligent upgrading has arrived.The volume of gynecological laparoscopic surgeries has maintained steady growth in recent years, driving continuous expansion of the uterine manipulator market. Currently, disposable balloon uterine manipulators dominate the market. Hangzhou Kangji, a leading domestic manufacturer, holds the majority share, while imported products, represented by CooperSurgical’s RUMI System, primarily target the high-end segment.

However, overall, the technological iteration of existing products remains at the "single-use + balloon" stage, inElectric Adjustment, Adaptive Aperture, Linked FixationThere are significant gaps in intelligent features. This is precisely the core breakthrough of this patented technology.

According to the public information, this patent addresses the pain points of traditional instruments through three core innovations: first,Electric Steering, achieving large-angle left-right oscillation via a built-in steering motor in the main support rod, thereby overcoming the motion limitations of traditional uterine manipulators; secondly,Aperture Adaptive, the uterine manipulator cup is adjustable in size, allowing it to accommodate different patients without the need to replace accessories; thirdly,Linked Fixation, the opening and closing of the uterine manipulator rod is synchronized with the elevation and lowering of the uterine cup, forming a stable limit position against the inner wall of the uterus.

These three points precisely address the functional gaps in current market products.

Hunan Kemaisen Medical specializes in minimally invasive gynecological surgical instruments. For this device manufacturer, which is still in the strategic layout phase, spending RMB 200,000 to acquire a patent seems more like aProduct Positioning。

On one hand, the market entry barrier for laparoscopic uterine manipulators is relatively low, with several mature domestic companies already established. If Hunan Kemaisen Medical Technology Co., Ltd. were to develop such a device from scratch, it would entail a long development cycle and substantial investment; therefore, directly acquiring mature patents represents a more efficient pathway. On the other hand, the three functional innovations embodied in this patent offer differentiated competitiveness in the current market, creating an opportunity to carve out a niche if commercialization proceeds smoothly.

However, challenges remain: as a new entrant, Kemaisen requires time to cultivate its distribution channels and brand awareness. The RMB 200,000 invested in patents is merely the first step; subsequent costs for clinical promotion and channel expansion may far exceed this amount.

Whether Kemaisen can recoup its investment depends on its execution speed and resource integration capabilities.